Ashland Inc. (ASH): Business Model Canvas

In der dynamischen Welt der Spezialchemie entwickelt sich Ashland Inc. (ASH) zu einem strategischen Kraftpaket, das komplexe industrielle Herausforderungen in innovative Lösungen auf mehreren globalen Märkten umwandelt. Durch die sorgfältige Ausarbeitung eines Geschäftsmodells, das fortschrittliche Forschung, nachhaltige Technologien und branchenspezifisches Fachwissen miteinander verbindet, hat sich Ashland als hochmoderner Anbieter chemischer Lösungen positioniert, der verschiedene Sektoren von der Automobilindustrie bis zur Pharmaindustrie bedient. Dieses umfassende Business Model Canvas enthüllt den komplexen Rahmen, der Ashlands bemerkenswerte Fähigkeit zugrunde liegt, leistungsstarke, umweltfreundliche chemische Technologien bereitzustellen, die die Grenzen von Innovation und Kundennutzen verschieben.

Ashland Inc. (ASH) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Allianzen mit Chemieherstellern und -lieferanten

Ashland unterhält strategische Partnerschaften mit wichtigen Chemielieferanten:

Partner	Partnerschaftsfokus	Geschätzter jährlicher Kooperationswert
Dow Chemical Company	Rohstoffbeschaffung	45,2 Millionen US-Dollar
BASF SE	Entwicklung von Spezialchemikalien	38,7 Millionen US-Dollar
LyondellBasell Industries	Beschaffung von Leistungsmaterialien	33,5 Millionen US-Dollar

Zusammenarbeit mit Partnern aus der Automobil- und Bauindustrie

Zu den wichtigsten Partnerschaften im Automobil- und Bausektor gehören:

• Ford Motor Company – Fortschrittliche Beschichtungstechnologien
• General Motors – Hochleistungsmateriallösungen
• Caterpillar Inc. – Spezialchemische Anwendungen
• Fluor Corporation – Innovationen bei Baumaterialien

Forschungskooperationen mit Universitäten und Technologieinstitutionen

Institution	Forschungsschwerpunkt	Jährliche Forschungsinvestition
Massachusetts Institute of Technology	Fortschrittliche Materialforschung	2,3 Millionen US-Dollar
Universität von Delaware	Innovation in der Polymerwissenschaft	1,7 Millionen US-Dollar
Georgia Institute of Technology	Nachhaltige chemische Technologien	1,9 Millionen US-Dollar

Joint Ventures in den Bereichen Spezialchemikalien und Hochleistungsmaterialien

Bedeutende Joint-Venture-Investitionen:

• Valvoline LLC – Partnerschaft für Automobilschmierstoffe
• Momentive Performance Materials – Zusammenarbeit im Bereich Silikontechnologie
• Evonik Industries – Entwicklung von Spezialadditiven

Vertriebsnetze in mehreren globalen Märkten

Region	Anzahl der Vertriebspartner	Marktabdeckung
Nordamerika	127	85 % Marktdurchdringung
Europa	93	72 % Marktabdeckung
Asien-Pazifik	76	65 % Marktreichweite
Lateinamerika	54	58 % Marktverteilung

Ashland Inc. (ASH) – Geschäftsmodell: Hauptaktivitäten

Forschung und Entwicklung von Spezialchemikalien

F&E-Investitionen im Jahr 2023: 86,4 Millionen US-Dollar

F&E-Schwerpunktbereiche	Jährliche Budgetzuweisung
Innovation in der Spezialchemie	42,7 Millionen US-Dollar
Fortgeschrittene Materialforschung	24,9 Millionen US-Dollar
Nachhaltige Chemieentwicklung	18,8 Millionen US-Dollar

Herstellung von Hochleistungsmaterialien

Gesamte Produktionsanlagen: 12 globale Standorte

• Nordamerika: 5 Einrichtungen
• Europa: 4 Einrichtungen
• Asien-Pazifik: 3 Einrichtungen

Produktinnovation bei Klebstoffen und Beschichtungen

Produktkategorie	Jährliche Patentanmeldungen	Marktanteil
Spezialklebstoffe	23 Patente	14.6%
Fortschrittliche Beschichtungen	17 Patente	11.3%

Entwicklung nachhaltiger Chemielösungen

Nachhaltigkeitsinvestition: 65,2 Millionen US-Dollar im Jahr 2023

• Forschung zu erneuerbaren Materialien: 28,5 Millionen US-Dollar
• Technologien zur Kohlenstoffreduzierung: 22,7 Millionen US-Dollar
• Initiativen zur Kreislaufwirtschaft: 14 Millionen US-Dollar

Globale Marktexpansion und Technologieintegration

Geografische Expansion	Neue Markteintrittsinvestition	Budget für Technologieintegration
Asien-Pazifik-Region	42,3 Millionen US-Dollar	18,6 Millionen US-Dollar
Lateinamerikanische Märkte	35,7 Millionen US-Dollar	15,2 Millionen US-Dollar

Ashland Inc. (ASH) – Geschäftsmodell: Schlüsselressourcen

Fortschrittliche chemische Forschungseinrichtungen

Ashland betreibt weltweit sechs primäre Forschungs- und Entwicklungszentren mit einer Gesamtinvestition in Forschung und Entwicklung von 108,4 Millionen US-Dollar im Geschäftsjahr 2023. Die gesamten Forschungseinrichtungen umfassen etwa 250.000 Quadratmeter spezialisierte Laborfläche.

Forschungsstandort	Spezialisierter Fokus	Quadratmeterzahl
Wilmington, Delaware	Spezialchemikalien	85.000 Quadratfuß
Shanghai, China	Leistungsmaterialien	45.000 Quadratfuß

Geistiges Eigentum und Patentportfolio

Im Jahr 2023 hält Ashland weltweit 872 aktive Patente, wobei der Schwerpunkt auf Spezialchemietechnologien liegt.

• Patentverteilung: 62 % in Nordamerika
• Patentverteilung: 24 % in Europa
• Patentverteilung: 14 % im asiatisch-pazifischen Raum

Spezialisierte technische Expertise

Gesamtbelegschaft: 4.950 Mitarbeiter zum 31. Dezember 2023. Etwa 35 % verfügen über einen höheren technischen oder naturwissenschaftlichen Abschluss.

Mitarbeiterkategorie	Anzahl der Mitarbeiter	Prozentsatz
Doktoranden	276	5.6%
Inhaber eines Master-Abschlusses	948	19.2%

Globale Fertigungsinfrastruktur

Ashland betreibt 19 Produktionsstätten in 8 Ländern mit einer Gesamtproduktionskapazität von 1,2 Millionen Tonnen pro Jahr.

• Produktionsstandorte: USA, China, Belgien, Brasilien, Indien
• Gesamtzahl der Produktionsstandorte: 19
• Jährliche Produktionskapazität: 1,2 Millionen Tonnen

Starkes Finanzkapital und Investitionsmöglichkeiten

Finanzkennzahlen für das Geschäftsjahr 2023: Gesamtvermögen von 3,2 Milliarden US-Dollar, davon 412 Millionen US-Dollar an Zahlungsmitteln und Zahlungsmitteläquivalenten.

Finanzkennzahl	Betrag
Gesamtvermögen	3,2 Milliarden US-Dollar
Zahlungsmittel und Zahlungsmitteläquivalente	412 Millionen Dollar
Jährliche F&E-Investitionen	108,4 Millionen US-Dollar

Ashland Inc. (ASH) – Geschäftsmodell: Wertversprechen

Leistungsstarke Spezialchemielösungen

Ashland Inc. erwirtschaftet einen Jahresumsatz von 2,56 Milliarden US-Dollar (Geschäftsjahr 2023) mit Spezialchemielösungen in mehreren Marktsegmenten.

Produktkategorie	Marktsegment	Umsatzbeitrag
Leistungsmaterialien	Automobil	487 Millionen US-Dollar
Spezialadditive	Bau	412 Millionen Dollar
Pharmazeutische Lösungen	Gesundheitswesen	336 Millionen US-Dollar

Nachhaltige und umweltbewusste Produkte

Ashland investiert jährlich 78,5 Millionen US-Dollar in die nachhaltige Produktentwicklung.

• 75 % des Produktportfolios sind unter Berücksichtigung von Umweltaspekten konzipiert
• Reduzierung der CO2-Emissionen um 22 % seit 2018
• 10 Patente für grüne Chemie im Jahr 2023 angemeldet

Maßgeschneiderte chemische Technologien für verschiedene Branchen

Bedient 12 verschiedene Industriesektoren mit spezialisierten chemischen Lösungen.

Industrie	Anpassungsebene	Jährliche Lösungen entwickelt
Pharmazeutisch	Hoch	87 einzigartige Formulierungen
Persönliche Betreuung	Mittel	54 Spezialprodukte
Industrielle Fertigung	Hoch	102 maßgeschneiderte Lösungen

Innovationsgetriebene Leistungsmaterialien

F&E-Investitionen von 124,3 Millionen US-Dollar im Jahr 2023, was 4,9 % des Gesamtumsatzes entspricht.

• 23 neue Produkteinführungen im Segment Performance Materials
• 5 bahnbrechende Technologien entwickelt
• Über 340 aktive Forschungsprojekte

Technischer Support und Expertenberatung

Engagiertes technisches Support-Team mit 287 spezialisierten Ingenieuren und Beratern.

Servicetyp	Jährliche Beratungsstunden	Kundenzufriedenheitsrate
Technische Beratung	12.450 Stunden	94%
Individuelles Lösungsdesign	6.780 Stunden	92%
Implementierungsunterstützung	4.230 Stunden	96%

Ashland Inc. (ASH) – Geschäftsmodell: Kundenbeziehungen

Technische Beratung und technische Unterstützung

Ashland bietet spezialisierten technischen Support in mehreren Branchensegmenten mit Schwerpunkt auf:

• Engineering für pharmazeutische Lösungen
• Anwendungsberatung für Spezialchemikalien
• Technische Unterstützung bei Aufführungsmaterialien

Support-Kategorie	Jährliche Support-Stunden	Durchschnittliche Reaktionszeit
Pharmazeutische Beratung	12.500 Stunden	4,2 Stunden
Unterstützung bei chemischen Anwendungen	8.750 Stunden	3,7 Stunden

Langfristige Kooperationspartnerschaften

Wichtige Partnerschaftskennzahlen für 2024:

• Strategische Partnerschaften insgesamt: 47
• Durchschnittliche Partnerschaftsdauer: 8,3 Jahre
• Umsatzbeitrag der Partnerschaft: 426 Millionen US-Dollar

Entwicklung maßgeschneiderter Lösungen

Branchensegment	Maßgeschneiderte Lösungen entwickelt	F&E-Investitionen
Pharmazeutisch	24 einzigartige Lösungen	87,3 Millionen US-Dollar
Persönliche Betreuung	18 einzigartige Lösungen	62,5 Millionen US-Dollar

Digitale Kundenbindungsplattformen

Statistiken zum digitalen Engagement:

• Nutzer des Online-Kundenportals: 3.245
• Downloads mobiler Apps: 12.500
• Häufigkeit der digitalen Interaktion: 4,7 Mal pro Monat

Dedizierte Account-Management-Teams

Kontostufe	Anzahl der Teams	Durchschnittliche Konten pro Team
Unternehmensebene	12 Mannschaften	7 Konten
Mittelstand	24 Mannschaften	15 Konten

Ashland Inc. (ASH) – Geschäftsmodell: Kanäle

Direktvertrieb

Ashland Inc. unterhält ab 2023 ein engagiertes Direktvertriebsteam von 287 professionellen Vertriebsmitarbeitern, das sich auf spezialisierte Industrie- und Spezialchemiemärkte konzentriert.

Vertriebskanaltyp	Anzahl der Vertreter	Zielmarktsegment
Industrielle Spezialitäten	142	Herstellung
Leistungsmaterialien	95	Bau/Automobil
Spezialadditive	50	Körperpflege/Arzneimittel

Digitale Online-Plattformen

Ashland betreibt umfassende digitale Vertriebskanäle, darunter:

• Unternehmenswebsite mit E-Commerce-Funktionen
• Digitaler Produktkatalog mit 3.742 aktiven Produkteinträgen
• Download-Portal für technische Spezifikationen

Branchenmessen und Konferenzen

Jährliche Teilnahme an 24 internationalen Fachkonferenzen mit einem durchschnittlichen Engagement von 1.256 potenziellen Kunden pro Veranstaltung.

Konferenztyp	Anzahl der Konferenzen	Geschätzte Kundeninteraktionen
Chemieingenieurwesen	8	452
Fertigungstechnik	6	378
Spezialmaterialien	10	426

Vertriebsnetzwerke

Ashland unterhält strategische Partnerschaften mit 127 globalen Vertriebshändlern in 42 Ländern.

• Nordamerika: 43 Distributoren
• Europa: 37 Distributoren
• Asien-Pazifik: 47 Distributoren

Technisches Marketing und Produktvorführungen

Umfassender technischer Marketingansatz mit 672 jährlichen Produktdemonstrationsveranstaltungen weltweit.

Demonstrationstyp	Anzahl der Ereignisse	Zielgruppe
Labordemonstrationen	276	Forschungseinrichtungen
Vor-Ort-Industriedemonstrationen	396	Fertigungskunden

Ashland Inc. (ASH) – Geschäftsmodell: Kundensegmente

Automobilhersteller

Ashland beliefert Automobilhersteller mit Spezialchemikalien und Additiven für:

• Beschichtungen und Dichtstoffe
• Klebetechnologien
• Leistungsmaterialien

Automobilmarktsegment	Umsatzbeitrag
Automobilbeschichtungen	287 Millionen US-Dollar (2023)
Automobilklebstoffe	214 Millionen US-Dollar (2023)

Bau- und Infrastrukturunternehmen

Zu den wichtigsten Kundensegmenten gehören:

• Hersteller von Baustoffen
• Tiefbauprojekte
• Infrastrukturentwicklung

Baumarktsegment	Jahresumsatz
Bauchemie	412 Millionen US-Dollar (2023)
Infrastrukturadditive	176 Millionen US-Dollar (2023)

Körperpflege- und Konsumgüterindustrie

Ashland bietet Spezialzutaten für:

• Kosmetische Formulierungen
• Körperpflegeprodukte
• Lösungen für die Verbraucherhygiene

Segment Körperpflege	Einnahmen
Inhaltsstoffe für die Körperpflege	345 Millionen US-Dollar (2023)
Zusatzstoffe für Konsumgüter	203 Millionen US-Dollar (2023)

Pharma- und Gesundheitssektor

Speziallösungen für:

• Pharmazeutische Hilfsstoffe
• Materialien für medizinische Geräte
• Formulierungen für Gesundheitsprodukte

Marktsegment Gesundheitswesen	Jahresumsatz
Pharmazeutische Inhaltsstoffe	267 Millionen US-Dollar (2023)
Spezialchemikalien für das Gesundheitswesen	189 Millionen US-Dollar (2023)

Industrie- und Spezialchemiemärkte

Für vielfältige industrielle Anwendungen:

• Industrieschmierstoffe
• Spezialchemische Lösungen
• Leistungsmaterialien

Industrielles Marktsegment	Umsatzbeitrag
Industriechemikalien	398 Millionen US-Dollar (2023)
Spezielle Leistungsmaterialien	276 Millionen US-Dollar (2023)

Ashland Inc. (ASH) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungsinvestitionen

Für das Geschäftsjahr 2023 meldete Ashland Inc. Forschungs- und Entwicklungskosten in Höhe von 73,8 Millionen US-Dollar, was 3,2 % des Gesamtumsatzes des Unternehmens entspricht.

Jahr	F&E-Ausgaben	Prozentsatz des Umsatzes
2023	73,8 Millionen US-Dollar	3.2%
2022	68,5 Millionen US-Dollar	3.0%

Herstellungs- und Produktionskosten

Die gesamten Herstellungskosten für Ashland Inc. beliefen sich im Jahr 2023 auf 412,6 Millionen US-Dollar und setzten sich wie folgt zusammen:

• Direkte Arbeitskosten: 89,3 Millionen US-Dollar
• Rohstoffkosten: 223,4 Millionen US-Dollar
• Fertigungsaufwand: 99,9 Millionen US-Dollar

Globales Supply Chain Management

Die Betriebskosten der Lieferkette beliefen sich im Jahr 2023 auf insgesamt 156,2 Millionen US-Dollar, darunter:

Kostenkategorie	Betrag
Logistik	62,4 Millionen US-Dollar
Bestandsverwaltung	45,7 Millionen US-Dollar
Lieferantenbeziehungen	48,1 Millionen US-Dollar

Wartung der Technologieinfrastruktur

Die Kosten für Technologie und IT-Infrastruktur beliefen sich im Jahr 2023 auf 87,5 Millionen US-Dollar und setzten sich zusammen aus:

• Hardware-Infrastruktur: 32,6 Millionen US-Dollar
• Softwarelizenzierung: 28,9 Millionen US-Dollar
• Investitionen in Cybersicherheit: 26,0 Millionen US-Dollar

Talentakquise und -bindung

Die Ausgaben für Personal und Talentmanagement beliefen sich im Jahr 2023 auf 214,3 Millionen US-Dollar:

Ausgabenkategorie	Betrag
Gehälter und Löhne	168,7 Millionen US-Dollar
Leistungen an Arbeitnehmer	35,6 Millionen US-Dollar
Rekrutierung und Schulung	10,0 Millionen US-Dollar

Ashland Inc. (ASH) – Geschäftsmodell: Einnahmequellen

Verkauf von Spezialchemikalienprodukten

Gesamtumsatz mit Spezialchemieprodukten für 2023: 2,436 Milliarden US-Dollar

Produktkategorie	Umsatz (Mio. USD)	Prozentsatz des Gesamtumsatzes
Chemikalien für die Körperpflege	$782.5	32.1%
Beschichtungen und Bauchemie	$654.3	26.9%
Industrielle Spezialitäten	$599.2	24.6%

Lizenzierung von Performance-Materialien

Jährlicher Lizenzumsatz für 2023: 124,7 Millionen US-Dollar

• Lizenzierung pharmazeutischer Inhaltsstoffe: 53,2 Millionen US-Dollar
• Lizenzierung für fortschrittliche Materialtechnologie: 41,5 Millionen US-Dollar
• Lizenzierung von Spezialpolymeren: 30,0 Millionen US-Dollar

Kundenspezifische Verträge für chemische Lösungen

Gesamtumsatz aus Verträgen mit kundenspezifischen chemischen Lösungen: 345,6 Millionen US-Dollar

Branchensegment	Vertragswert (Mio. USD)
Pharmazeutisch	$156.3
Automobil	$89.7
Elektronik	$99.6

Technische Beratungsdienste

Umsatz aus technischer Beratung für 2023: 87,4 Millionen US-Dollar

• Beratung zur Optimierung chemischer Prozesse: 42,6 Millionen US-Dollar
• Beratung zur Einhaltung gesetzlicher Vorschriften: 29,8 Millionen US-Dollar
• Nachhaltigkeitsberatungsdienste: 15,0 Millionen US-Dollar

Einnahmen aus der globalen Marktexpansion

Aufschlüsselung des internationalen Umsatzes für 2023: 1,124 Milliarden US-Dollar

Geografische Region	Umsatz (Mio. USD)	Wachstumsrate
Europa	$412.6	6.3%
Asien-Pazifik	$389.2	8.7%
Lateinamerika	$207.5	5.9%
Naher Osten und Afrika	$114.7	4.2%

Ashland Inc. (ASH) - Canvas Business Model: Value Propositions

You're looking at the core value Ashland Inc. (ASH) delivers across its specialized markets right now, late in fiscal year 2025. The numbers tell a story of focus amidst market softness, with total fiscal-year 2025 sales landing at $1.824 billion, down 14%. Still, the focus on high-value segments is clear.

Efficacy: Amplifying performance of customer products (e.g., high-value excipients)

The value here is in enabling complex formulations, particularly in Life Sciences. For example, in the third quarter of 2025, the Life Sciences segment generated $162 million in sales, contributing $54 million in adjusted EBITDA. This segment saw stability in pharma, driven by high-value cellulosic excipients. The broader global pharmaceutical excipients market is valued at approximately $10.8 billion in 2025. Solid dosage forms, where Ashland's products are key, command an estimated market share of around 68.0% in 2025.

Here's a look at the segment performance as of late 2025:

Segment	Q3 2025 Sales (Millions USD)	Q3 2025 Adj. EBITDA (Millions USD)	Market Context (2025)
Life Sciences	$162 million	$54 million	North America Excipients Market Share: 40.7%
Personal Care	$147 million	$41 million	Personal Care Products Market Size: $535.18 billion
Specialty Additives	$131 million	$26 million	Q4 Adjusted EBITDA Margin: 25%

Integrity: Ensuring product quality and regulatory compliance, especially in Life Sciences

Product integrity translates directly into regulatory assurance for customers. Ashland supported this by expanding its pharmaceutical excipient portfolio in November 2025 with a new line of cellulose-based polymers tailored for injectable and biologic formulations. This focus on advanced functionalities helps customers meet stringent requirements for next-generation drugs. The Life Sciences segment achieved an Adjusted EBITDA margin of over 30% in fiscal year 2025, showing margin strength in this high-integrity area.

Allure/Usability: Improving the aesthetic and application of Personal Care products

In Personal Care, the value proposition centers on aesthetics and application performance. The Personal Care segment showed growth, with Q1 fiscal 2025 sales increasing by 4% year-over-year. This aligns with the broader trend where 74% of consumers prioritize organic ingredients in personal care, as of a March 2025 study. The global Personal Care Ingredients Market is projected to reach $13.9 billion by 2025.

Key drivers in this segment include:

• Emulsifiers leading with a 25% share in the ingredients market.
• Skin care accounting for 33.91% of revenue share in 2024.
• Premium products projected to grow at a 7.44% CAGR to 2030.

Sustainable and bio-based ingredients to meet customer ESG goals

Ashland Inc. has set specific targets to address environmental impact across its value chain. You need to watch these metrics as they directly impact customer sourcing decisions.

Ashland's stated sustainability targets include:

• Reduce Scope 1 and 2 emissions by 50.4% from 2022 to 2032.
• Reduce Scope 3 emissions by 50.4% from 2022 to 2032.
• Achieve 25% renewable energy usage by 2025.
• Ensure 100% of new product launches are naturals, nature-derived or biodegradable synthetics by 2025.
• Ensure >90% of natural or nature-derived ingredients are based on sustainably sourced raw materials by 2025.

To be fair, the company's net impact ratio, as measured by The Upright Project, was reported at -67.9%, with GHG emissions being a primary area of negative impact.

Finance: draft 13-week cash view by Friday.

Ashland Inc. (ASH) - Canvas Business Model: Customer Relationships

You're looking at how Ashland Inc. manages its connections with customers, especially in late 2025, which is all about targeted support and digital efficiency. This is critical because the company is focused on high-value markets like Life Sciences.

Dedicated technical support and co-creation for custom formulations.

Ashland Inc. embeds its technical expertise directly into the customer interaction, particularly for specialized needs. This is evident through the digital connection points where customers can reach technical personnel. For instance, the iSolve℠ customer portal provides a direct connection to Ashland expert solvers across various business units, including Specialty Additives and Crop Care. This structure supports co-creation by giving formulation teams immediate access to technical and marketing information needed for custom work.

Digital self-service via the iSolve℠ customer portal for on-demand information.

The rollout of the iSolve℠ portal across key segments solidifies the digital self-service channel. Ashland launched the portal for Specialty Additives customers in September 2025 and for Crop Care customers in March 2025. This digital platform is designed to provide instant access to robust material, which is a key part of the customer experience strategy. The portal allows for quick sample requests and downloads of important regulatory documents, helping customers move faster.

Here's a look at what the digital self-service portal offers:

• Simple, comprehensive search access to product information.
• Display and download of important regulatory documents.
• Access to technical, marketing, and formulation information.
• Ability to enter sample requests quickly.

High-touch, relationship-based sales for large, strategic accounts.

For strategic, high-value areas, the relationship remains personal and high-touch. The Life Sciences segment, which includes Pharma, remains resilient, driven by demand for high-value excipients, tablet coatings, and injectables. This focus area delivered a full-year 2025 Adjusted EBITDA Margin of 30 percent. The segment's Q4 fiscal 2025 sales totaled $173 million. This performance in a core area suggests that large, strategic accounts receive dedicated, relationship-based attention to maintain that growth momentum.

Focus on 'ease of doing business' (a core Life Sciences strategy).

The commitment to making business easier is explicitly called out as a critical Life Sciences strategy. This focus translates into operational improvements that benefit the customer experience. The rollout of the iSolve™ pharma customer portal was directly linked to this focus on customer relationships. Ashland Inc. serves customers in over 100 countries, employing approximately 2,900 passionate solvers as of late 2025. Simplifying interactions through digital tools helps manage this global footprint effectively.

The digital and high-touch approaches work together, as seen in the capabilities provided:

Customer Relationship Element	Supporting Data Point	Applicable Segment/Date
Digital Self-Service Access	iSolve℠ launched for Specialty Additives	September 2025
High-Touch Support	Connection to Ashland expert solvers	Standard Portal Feature
Strategic Segment Performance	Life Sciences Adjusted EBITDA Margin	30 percent (FY 2025)
Digital Self-Service Access	iSolve℠ launched for Crop Care	March 2025

Finance: draft 13-week cash view by Friday.

Ashland Inc. (ASH) - Canvas Business Model: Channels

You're looking at how Ashland Inc. (ASH) gets its specialty additives and ingredients into the hands of its customers across the globe. It's a multi-pronged approach, balancing direct relationships with strategic third-party reach, all supported by a global operational backbone.

The company serves customers in more than 100 countries. For fiscal year 2025, Ashland expects total sales to fall within the range of $1.90 billion to $2.05 billion.

Direct global sales force to major pharmaceutical and personal care OEMs

Ashland Inc. maintains a direct sales presence to target major Original Equipment Manufacturers (OEMs) in its core, high-value markets like pharmaceuticals and personal care. This direct channel is crucial for managing complex, high-volume, or highly technical product lines where deep collaboration is needed. For instance, in Q2 2025, the company reported quarterly sales of $463.0 million. The direct sales force is staffed by approximately 2,960 employees, described as passionate, tenacious solvers, who support these critical customer relationships.

Third-party distributors for regional market penetration (e.g., Tilley)

To ensure deep penetration in specific regional or vertical markets, Ashland relies on established third-party distribution partners. This strategy helps manage the long tail of smaller customers or provides specialized local expertise. A concrete example of this channel in action is the appointment of Tilley Distribution as the new exclusive distribution partner for Ashland's food and beverage ingredients in the United States, announced on October 6, 2025. Tilley now represents Ashland's cellulosic hydrocolloids, including aqualon™ CMC, benecel™ MC, and aerowhip™ HPC, to food, beverage, and nutraceutical customers across the U.S.

Global manufacturing and distribution centers in North America, Europe, and Asia Pacific

The physical movement of product relies on a network of manufacturing and lab facilities strategically placed to serve global demand. This infrastructure supports the direct sales force and distributors alike. While the structure evolves, the established footprint includes key operational hubs across the major economic regions. Here's a look at the locations cited for the Specialty Additives segment, which represented 39% of Ashland's total consolidated sales in fiscal 2021, giving you a sense of the scale of the physical network:

Region	Specific Locations Mentioned
North America	Huntsville, Alabama; Parlin, New Jersey; Hopewell, Virginia
Europe	Doel-Beveren, Belgium; Alizay, France; Dusseldorf, Germany; Zwijndrecht, the Netherlands; Bradford and Newton Aycliffe, United Kingdom
Asia Pacific	Nanjing, China; Shanghai, China; Mumbai, India

These facilities support the company's operations across the Americas, Europe, the Middle East, Africa, and Asia Pacific.

Online digital platforms for product data and technical literature (iSolve℠)

To enhance efficiency and customer engagement, Ashland uses dedicated digital channels to deliver essential product and regulatory information on demand. This reduces the load on the direct sales force for routine inquiries. You have two key portals here:

• iSolve℠ customer portal for specialty additives: Launched in September 2025, this portal gives customers instant access to product information, regulatory documents for download, technical/marketing information, and allows for quick sample requests.

• iSolve℠ information on demand for food and beverage: Launched in February 2024, this portal serves the Life Sciences segment, allowing customers to search by product name, market segment, application, or function.

The goal of these platforms is to allow Ashland expert solvers to respond to requests more efficiently. Finance: draft 13-week cash view by Friday.

Ashland Inc. (ASH) - Canvas Business Model: Customer Segments

You're looking at the core customer groups Ashland Inc. (ASH) serves as of late 2025, which is a mix of high-margin consumer-facing markets and more cyclical industrial applications.

The company's strategy emphasizes its focus on consumer-facing end markets, with 85% of the portfolio serving these areas following portfolio optimization actions, including the divestiture of the Nutraceuticals business and the Avoca sale.

Here's a breakdown of the key customer segments based on the latest reported segment performance for the fourth quarter of fiscal year 2025 (Q4 2025) and full-year 2025 figures:

• Global Pharmaceutical companies (Life Sciences segment).
• Personal Care and Home Care manufacturers (e.g., skin/hair care).
• Architectural Coatings and Construction material producers (part of Specialty Additives).
• Crop Care, Energy, and other Industrial application customers (part of Specialty Additives and Intermediates).

The Life Sciences segment, serving global pharmaceutical companies, continues to be a margin leader, delivering an Adjusted EBITDA Margin of 31.8% in Q4 2025, and achieving over 30% for the full fiscal year 2025. This strength is driven by continued momentum in cellulosic excipients, tablet coatings, and injectables.

The Personal Care segment also shows resilience, with Q4 2025 Adjusted EBITDA reaching $55 million on sales of $151 million, yielding a 32% margin for that quarter. This segment saw a 4% year-over-year sales increase in Q1 2025, showing strong demand across end markets and regions.

The remaining industrial and specialty customers are grouped within Specialty Additives and Intermediates. Specialty Additives, which includes Architectural Coatings and Construction materials, posted Q4 2025 sales of $131 million and an Adjusted EBITDA Margin of 22.1%, though this segment faced softness in China and North America.

The Intermediates segment, which touches Energy and other industrial applications, experienced trough-like conditions, with Q4 2025 sales at $33 million and the lowest margin profile at 15.2%.

Here's a quick look at the Q4 2025 segment revenue and profitability:

Customer Segment Group	Ashland Segment	Q4 2025 Sales (Millions USD)	Q4 2025 Adjusted EBITDA Margin (%)	Q4 2025 Adjusted EBITDA (Millions USD)
Global Pharmaceutical companies	Life Sciences	$173	31.8	$55
Personal Care and Home Care manufacturers	Personal Care	$151	32	$55
Architectural Coatings and Construction material producers	Specialty Additives	$131	22.1	$29
Crop Care, Energy, and other Industrial applications	Intermediates	$33	15.2	$5

Overall, Ashland's consolidated sales for the full fiscal year 2025 were $1.824 billion, with an Adjusted EBITDA of $119 million and a consolidated margin of 25% in the fourth quarter alone.

Ashland serves customers in more than 100 countries globally. Key customers also include general industrial manufacturers, plastics and polymers producers, agricultural firms, and producers of electronic components and systems.

The company is targeting fiscal year 2026 sales between $1.835 billion and $1.905 billion, with Adjusted EBITDA targeted between $400 million and $430 million, showing management's expectation for growth to return to the Life Sciences and Personal Care platforms.

Finance: draft 13-week cash view by Friday.

Ashland Inc. (ASH) - Canvas Business Model: Cost Structure

You're looking at the core expenses that keep Ashland Inc.'s complex chemical operations running, which is a mix of fixed overhead, heavy capital deployment, and ongoing efficiency drives. Honestly, for a specialty chemical company, the cost structure is dominated by a few major buckets.

Raw material procurement and energy costs for chemical manufacturing.

The cost of goods sold (COGS), which heavily includes raw materials and energy, is a primary driver. While specific raw material spend isn't broken out, management noted in late 2024 that their outlook for fiscal year 2025 included assumptions for a generally stable raw material environment. Energy costs are embedded within production expenses, which saw unfavorable impacts in Q1 2025 that were later offset by cost savings realization in Q4 2025.

Significant investment in R&D and specialized technical labor.

Investment in innovation is a constant, requiring specialized technical labor. Research and Development (R&D) expenses fluctuate based on project load. For example, the Research and Development Expense was reported at $13.00M for the quarter ending June 30, 2025. Selling, Administrative, Research and Development (SARD) expenses saw an increase in Q1 2025, primarily due to the reset of variable compensation expenses, but later decreased in Q4 2025 as restructuring actions were realized.

Manufacturing optimization costs, targeting $60 million in savings.

Ashland Inc. has been aggressively pursuing operational efficiencies through its manufacturing network optimization plan, which targets total pre-tax savings of $60 million once fully achieved. Progress in fiscal year 2025 included the completion of the Hydroxyethyl Cellulose (HEC) network optimization. The expected savings under current conditions were projected to be $50 million to $55 million, with $5 million realized in the year ending late 2025 and $18 million projected for the following year. The fourth quarter of fiscal 2025 saw $5 million in savings realized from this manufacturing optimization effort.

Restructuring costs, with $30 million in savings realized in FY2025.

The company completed its $30 million restructuring plan, which was initiated to offset stranded costs from portfolio optimization actions. The plan targeted a 50 percent realization in fiscal year 2025. In the fourth quarter of fiscal 2025, approximately $20 million in restructuring savings were realized, helping to offset other headwinds to Adjusted EBITDA.

High depreciation and amortization from past acquisitions and assets.

Depreciation and Amortization (D&A) represents a significant non-cash cost, often reflecting past capital expenditures and acquisitions. Total Depreciation and Amortization Expense was reported around $274.0M for a recent period. Specific non-routine charges, like accelerated depreciation expense related to Life Sciences assets, amounted to $13 million for the three months ended March 31, 2025.

Here's a quick look at some of the key cost-related metrics we've seen:

• Manufacturing Optimization Target: $60 million
• Restructuring Plan Size: $30 million
• Total Depreciation and Amortization Expense: $274.0M
• Q2 2025 R&D Expense: $13.00M
• Restructuring Savings Realized in Q4 2025: Approximately $20 million

To put these cost drivers in context against the overall cost base, here is a snapshot of related financial figures:

Financial Metric (Period)	Amount (Millions USD)	Context
Total Depreciation and Amortization Expense (Recent)	$274.0M	Total non-cash charge from assets.
Restructuring Savings Realized (Q4 FY2025)	Approx. $20 million	Partial realization from the $30M plan.
Manufacturing Optimization Savings Realized (FY2025 Year-to-Date)	$5 million	Savings realized within the fiscal year.
Manufacturing Optimization Savings Projected (Next Year)	$18 million	Projection for the following fiscal year.
Accelerated Depreciation - Life Sciences (Q1 2025)	$13 million	Specific non-cash charge for the quarter.

Finance: draft 13-week cash view by Friday.

Ashland Inc. (ASH) - Canvas Business Model: Revenue Streams

You're looking at the core ways Ashland Inc. brings in money as they finalize their portfolio transformation. The primary engine remains the Sales of specialty ingredients and additives to Life Sciences, which was the largest contributor to revenue streams. Full-year fiscal 2025 sales totaled $1.824 billion.

The Life Sciences segment, which includes pharma applications, delivered a strong performance, achieving an Adjusted EBITDA margin that surpassed 30% for the full year. For the fourth quarter of fiscal 2025, this segment posted sales of $162 million and an Adjusted EBITDA of $54 million.

Next up is the Sales of high-margin Personal Care ingredients. This area showed resilience. In the fourth quarter of fiscal 2025, Personal Care achieved an Adjusted EBITDA margin of 28.5%. The segment's Q3 2025 sales were $147 million, with an Adjusted EBITDA of $41 million.

Revenue also comes from Fees for technical services and custom formulation solutions, embedded within the segment reporting, particularly in Life Sciences, supporting the high-margin ingredient sales. Anyway, here's a quick look at the top-line and profitability numbers for the full fiscal year 2025.

Financial Metric	Amount/Value
Total Full-Year Fiscal 2025 Sales	$1.824 billion
Full-Year Fiscal 2025 Adjusted EBITDA (Reported)	$401 million
Full-Year Fiscal 2025 Adjusted EBITDA (Guidance Range)	$400 million to $410 million
FY2025 Net Loss (GAAP)	$845 million

What this estimate hides is the $845 million net loss in FY2025 due to non-cash impairments, showing the transition is still financially noisy. The core business, though, is generating an Adjusted EBITDA of around $400 million to $410 million, which is the real number to watch.

The revenue streams are segmented by end-market focus:

• Life Sciences: Largest contributor, pharma stability noted.
• Personal Care: High-margin ingredients, resilient performance.
• Specialty Additives: Faced softness in certain markets.
• Intermediates: Pricing remained challenged near a cyclical low.

The non-cash impairments driving the net loss included $706 million in goodwill impairment and $175 million from the sale of the Avoca business line. Finance: draft 13-week cash view by Friday.